Welcome to our dedicated page for Medicinova SEC filings (Ticker: MNOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 300-page biotech filing packed with clinical data, patent charts, and dilution tables is tough. MediciNova SEC filings explained simply is exactly what investors need when trial milestones and cash-runway questions matter most. Stock Titan tackles the complexity head-on, turning every MediciNova annual report 10-K simplified, MediciNova quarterly earnings report 10-Q filing, and MediciNova 8-K material events explained into clear insights you can act on.
Our AI reads the fine print so you don鈥檛 have to. Get real-time alerts the moment MediciNova Form 4 insider transactions real-time hit EDGAR, follow MediciNova executive stock transactions Form 4 to gauge management confidence, and see risk-factor summaries without wading through legal language. Interactive dashboards connect R&D spend, partnership revenue and share-issuance data from each MediciNova earnings report filing analysis, while keyword search lets you pull trial endpoints in seconds鈥攑erfect for understanding MediciNova SEC documents with AI.
Every filing type is covered and continuously updated:
- 10-K & 10-Q: track phase-specific R&D outlays
- 8-K: instant trial-result disclosures
- Form 4: MediciNova insider trading Form 4 transactions spotlight buying or selling before catalysts
- DEF 14A: MediciNova proxy statement executive compensation tied to clinical milestones
Whether you鈥檙e screening for dilution risk, comparing cash burn versus pipeline breadth, or timing entries around FDA updates, Stock Titan鈥檚 AI-powered summaries, expert annotations, and exportable tables deliver the context serious biotech investors demand.
MediciNova, Inc. (MNOV) files an S-1 describing its clinical-stage pipeline centered on MN-166 (ibudilast) and MN-001 (tipelukast) and a financing arrangement with YA. MN-166 showed positive Phase 2b SPRINT-MS results including a 48% reduction in whole brain atrophy versus placebo (p=0.04) and a 26% reduction in risk of confirmed disability progression (HR=0.74); results were published in the New England Journal of Medicine. Multiple additional MN-166 programs reported milestones: positive Phase 2 COVID-19 ARDS topline results (statistical significance on respiratory-failure-free and hospital discharge endpoints; two placebo deaths, none on drug), IND and Orphan Drug for glioblastoma with Phase 2 enrollment completed, and ongoing/additional addiction and ophthalmic studies. MN-001 holds Fast Track designation for NASH with fibrosis and has completed/initiated several Phase 2 studies with positive subgroup and preclinical findings.
On financing, the company may sell up to $30.0 million of common stock to YA under a Purchase Agreement (registration to cover up to 25,000,000 shares). If all 25,000,000 shares were outstanding, they would represent ~51.0% of total shares and ~52.5% of non-affiliate shares (as of Aug 11, 2025). The agreement also includes an Exchange Cap limiting issuance to 9,804,345 shares (~19.99%) absent shareholder approval or price conditions. The filing lists exhibits, prior SEC filings, and signatures.
Medicinova, Inc. reports key disclosures including business risks, capital structure, segment reporting and recent lease and equity arrangements. The company lists numerous risk factors such as inability to raise capital, failure to generate product revenues, clinical trial delays or failures, reliance on its MN-166 (ibudilast) and MN-001 (tipelukast) product candidates, dependence on third parties for trials, manufacturing and commercialization, intellectual property disputes, and international and regulatory risks. Common stock authorized is 100,000,000 shares with 49,046,246 shares issued and outstanding at June 30, 2025 and December 31, 2024. The CODM evaluates performance using consolidated net loss and functional expenses. The company amended its Tokyo office lease to a 14-month term for measurement purposes using a 6.51% incremental borrowing rate. There were 970,000 performance options outstanding tied to 2025 objectives and Black-Scholes inputs are disclosed. An equity sale agreement pays 3.5% of gross proceeds to the agent. The company states strategic priorities to develop MN-166 and MN-001 and pursue non-dilutive financing and partnerships.
Form 4 filed for Medicinova, Inc. (MNOV) discloses that director Hideki Nagao received an option grant for 20,000 shares of common stock on 16 June 2025 at an exercise price of $1.26 per share. The options expire on 16 June 2035 and vest in four equal tranches on 30 Sep 2025, 31 Dec 2025, 31 Mar 2026 and 30 Jun 2026, contingent upon continued board service. No shares were sold or otherwise disposed of, and Nagao鈥檚 beneficial ownership in derivative securities increases to 20,000 options following this single transaction. The filing represents routine equity-based compensation and does not indicate any change in company fundamentals or insider sentiment beyond standard alignment incentives.
Medicinova, Inc. (MNOV) 鈥� Form 4 insider filing
On 17 June 2025, director Carolyn Beaver was granted an option to purchase 20,000 shares of Medicinova common stock. The option鈥檚 exercise price is $1.26 per share and it will expire on 16 June 2035.
The award vests in four equal installments of 5,000 shares on the following dates, contingent on continued board service:
- 30 Sep 2025
- 31 Dec 2025
- 31 Mar 2026
- 30 Jun 2026
Following this grant, Beaver reports beneficial ownership of 20,000 derivative securities and no change in non-derivative holdings was disclosed.
The transaction was coded 鈥淎鈥� (grant) and filed as a single-reporting-person Form 4 on 20 June 2025. No 10b5-1 plan was indicated.
Investor takeaway: This appears to be a routine equity incentive award to align director interests with shareholders; the 20,000-share size is modest relative to Medicinova鈥檚 outstanding share count and therefore immaterial from a dilution standpoint.
FAQ
What is the current stock price of Medicinova (MNOV)?
What is the market cap of Medicinova (MNOV)?
